JP2024503727A5 - - Google Patents
Info
- Publication number
- JP2024503727A5 JP2024503727A5 JP2023543284A JP2023543284A JP2024503727A5 JP 2024503727 A5 JP2024503727 A5 JP 2024503727A5 JP 2023543284 A JP2023543284 A JP 2023543284A JP 2023543284 A JP2023543284 A JP 2023543284A JP 2024503727 A5 JP2024503727 A5 JP 2024503727A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- roflumilast
- pharmaceutical composition
- equivalent amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163199728P | 2021-01-20 | 2021-01-20 | |
| US63/199,728 | 2021-01-20 | ||
| PCT/US2022/013197 WO2022159632A1 (en) | 2021-01-20 | 2022-01-20 | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503727A JP2024503727A (ja) | 2024-01-26 |
| JP2024503727A5 true JP2024503727A5 (https=) | 2025-01-22 |
Family
ID=80447922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543284A Pending JP2024503727A (ja) | 2021-01-20 | 2022-01-20 | うつ病及び関連する状態の治療のための併用薬物戦略としてのｃＡＭＰシグナル伝達の強化 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220226302A1 (https=) |
| EP (1) | EP4281065A1 (https=) |
| JP (1) | JP2024503727A (https=) |
| WO (1) | WO2022159632A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4281065A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
| AU2024357688A1 (en) * | 2023-10-12 | 2026-04-23 | Alto Neuroscience, Inc. | Treatment of neuropsychiatric disorders with tilivapram |
| CN121816184A (zh) * | 2023-11-07 | 2026-04-07 | 傲拓神经科学公司 | 作为单一疗法或与抗精神病药剂组合使用伊达吡生来治疗伴有明显快感缺失的患者的精神或神经障碍 |
| TW202541796A (zh) * | 2023-12-28 | 2025-11-01 | 美商查斯治療公司 | 用於治療失樂症的組成物及方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2142817C1 (ru) | 1993-08-06 | 1999-12-20 | Коннот Лабораториз Лимитед | Инактивированные вакцины респираторно-синцитиального вируса |
| WO2006050057A2 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
| EP1940389A2 (en) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| FR2915098B1 (fr) | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere |
| JP2014525927A (ja) * | 2011-08-18 | 2014-10-02 | シャイアー アーゲー | 治療法に使用される５−ｈｔ４受容体アゴニスト及びｐｄｅ４阻害剤の組合せ |
| WO2014159776A1 (en) * | 2013-03-14 | 2014-10-02 | Cephalon, Inc. | Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride |
| AU2014307803A1 (en) * | 2013-08-16 | 2016-03-10 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
| JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
| EP3806835A1 (en) * | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| JP7821116B2 (ja) * | 2020-04-07 | 2026-02-26 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法 |
| EP4281065A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
-
2022
- 2022-01-20 EP EP22704089.6A patent/EP4281065A1/en active Pending
- 2022-01-20 WO PCT/US2022/013197 patent/WO2022159632A1/en not_active Ceased
- 2022-01-20 JP JP2023543284A patent/JP2024503727A/ja active Pending
- 2022-01-20 US US17/648,539 patent/US20220226302A1/en not_active Abandoned
- 2022-12-09 US US18/063,907 patent/US20230117508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503727A5 (https=) | ||
| CN112437659B (zh) | 用于治疗抑郁症的右美沙芬和安非他酮的组合 | |
| Langemark et al. | Sulpiride and paroxetine in the treatment of chronic tension‐type headache. An explanatory double‐blind trial | |
| TW200808696A (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| TWI826380B (zh) | Nk-1 拮抗劑組合物及用於治療抑鬱症之方法 | |
| JP2023535744A (ja) | 片頭痛の治療 | |
| WO2013063263A1 (en) | Pharmaceutical compositions for treating pain | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| US20180092916A1 (en) | Methods of treating disease-induced ataxia and non-ataxic imbalance | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| EP2343976A1 (en) | Methods of using sustained release aminopyridine compositions | |
| WO2011019845A1 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| CN114727989A (zh) | Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合 | |
| Smith-Apeldoorn et al. | Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study | |
| JP2015522077A5 (https=) | ||
| UA123623C2 (uk) | Способи лікування депресії із застосуванням модуляторів nmda | |
| JP2013536206A5 (https=) | ||
| JPWO2018221728A1 (ja) | アルツハイマー型認知症予防または治療剤 | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| TWI457123B (zh) | ４－｛３－［順式－六氫環戊并［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺與ｎｍｄａ受體拮抗劑之新結合及包含彼等之醫藥組合物 | |
| JP2023531930A5 (https=) | ||
| Graham et al. | Safety of tiotropium Respimat® in black or African-American patients with symptomatic asthma | |
| JP2005531594A5 (ja) | 慢性痛の治療用トリプルモノアミン再取り込み阻害剤 | |
| CN110461330A (zh) | 用于治疗亨廷顿氏病的PPARγ激动剂 | |
| JP2024518426A5 (https=) |